🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Spain
Clinical trial register · European Union · CTIS

Clinical Trials in Spain, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12490 total CTIS records — a stated recency window, not the full historical archive. Synced 25 Sep 2026, 03:16 UTC
2500
Shown in this register
most recently authorised
12,490
Total on CTIS
full historical archive
741
Phase III
within the shown window
Top member states
Spain 1016 France 881 Germany 860 Italy 735 Poland 585 Netherlands 531
Narrow the registerReset
Phase
Phase I 554 Phase I/II 213 Phase II 733 Phase III 741 Phase IV 259
Lead sponsor
AstraZeneca AB 62 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1016 France 881 Germany 860 Italy 735 Poland 585 Netherlands 531 Belgium 434 Czechia 327
All 28 states

Trials with a site in Spain

1016 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer
2025-523204-68-00HER2-positive breast cancer
Jazz Pharmaceuticals Ireland Limited
Neoplasms
Italy, Spain, Germany
22/12/2025
Phase III
A Phase 3, multicentre, randomised (1:1), parallel-group, active-controlled, central reader colonoscopist-blind study to evaluate the bowel cleansing efficacy, safety, tolerability, palatability, and acceptability of PLENVU® as compared to sodium picosulfate in paediatric participants from 1 to < 18 years of age in preparation for colonoscopy (CLARITY)
2025-522046-42-00Colonic disease
Norgine Limited
Digestive System Diseases
Poland, Netherlands, Hungary, Spain, Italy, Belgium, Germany, Croatia, Portugal
22/12/2025
Phase III
A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)
2025-521117-88-00Cardiovascular Disease
Amgen Inc.
Cardiovascular Diseases
France, Denmark, Germany, Spain, Italy, Netherlands
22/12/2025
Phase III
A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer
2024-515765-34-00English First-line extensive-stage small-cell lung cancer (…
BioNTech SE
Neoplasms
Poland, Spain, France, Italy, Germany, Romania, Netherlands
22/12/2025
Phase I
Phase Ib, non-randomized, single-arm, open-label, single-center clinical trial to evaluate the safety of the first-in-human administration of the combination of dendritic cell (DC) immunization pulsed with tumor lysate and CAR-T cells targeting IL13Ra2 in patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG)
2024-514052-32-00Patients with newly diagnosed diffuse intrinsic pontine gli…
Fundacio Sant Joan De Deu
Neoplasms
Spain
22/12/2025
Phase I/II
Phase 1/2 Study of Intravesical MK-3120 in BCG-Naïve or BCG-Exposed High-Risk Non-muscle Invasive Bladder Cancer
2025-520467-40-00High-risk non-muscle invasive bladder cancer (NMIBC) with c…
Merck Sharp & Dohme LLC
Neoplasms
Belgium, Greece, Austria, Spain, Norway, Netherlands, Italy, France
22/12/2025
Phase III
C2321008: A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF MEVROMETOSTAT (PF-06821497) WITH ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MEVPRO-3)
2024-519369-24-00METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER
Pfizer Inc.
Not possible to specify
Belgium, Finland, France, Germany, Netherlands, Bulgaria, Spain, Slovakia, Italy, Czechia, Poland, Greece
22/12/2025
Phase II
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Zasocitinib in Participants with Nonsegmental Vitiligo.
2025-522309-40-00Non-segmental vitiligo
Takeda Development Center Americas Inc.
Skin and Connective Tissue Diseases
Poland, Italy, Spain, France
19/12/2025
Phase III
IZABRIGHT-BLADDER01: A Randomized, Open-label, Phase 2/3 trial of Izalontamab Brengitecan versus platinum-based chemotherapy for metastatic urothelial cancer in participants with disease progression on or after an immunotherapy-based treatment
2025-522400-24-00Metastatic urothelial cancer
Bristol-Myers Squibb Services Unlimited Company
Female Urogenital Diseases and Pregnancy Complications
Ireland, Belgium, Germany, Italy, Norway, Spain, Austria, Sweden, France, Romania, Czechia
19/12/2025
Phase II
A Phase 1/2 Study to Evaluate STK-012 as a Single Agent and in Combination Therapy in Subjects with Front-line Advanced NSCLC and Other Selected Indications
2025-522632-14-00Non-small cell lung cancer (NSCLC)
Synthekine Inc.
Neoplasms
Ireland, Poland, Spain, Italy
19/12/2025
Phase IV
Phase IV, single-center, randomized, crossover clinical trial to validate the use of gadopiclenol versus gadobutrol in the evaluation of magnetic resonance imaging (MRI) diagnosis of perianal fistula associated with Crohn's disease
2025-523278-18-00Perianal fistula associated with Crohn's disease
Fundacio Hospital Universitari Vall D’Hebron Institut De Recerca
Diagnosis
Spain
18/12/2025
Phase I/II
Phase 1/2 multicenter, two-arms, open-label, dose-escalation study of IDP-121 in combination with chemotherapy in patients with relapsed small cell lung cancer (SCLC) (MYCrocytic)
2025-521902-17-00Unresectable/metastatic Small cell Lung Cancer (SCLC)
Idp Discovery Pharma S.L.
Neoplasms
Spain
18/12/2025
Phase III
A randomized, open-label, multicenter, Phase 3 trial of ivonescimab alone or ivonescimab with ligufalimab versus pembrolizumab for the first-line treatment of recurrent and/or metastatic head and neck squamous cell carcinoma(HNSCC)
2025-522996-27-00recurrent and/or metastatic squamous cell carcinoma of the …
Groupe Oncologie Radiotherapie Tete Cou
Neoplasms
France, Spain, Belgium
18/12/2025
Phase I/II
TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in combination with darolutamide versus darolutamide alone in patients with metastatic hormone-sensitive prostate cancer
2025-521873-15-00Metastatic hormone-sensitive prostate cancer
Novartis Pharma AG
Neoplasms
Hungary, Spain, Italy, Germany, France
18/12/2025
Phase I
A Phase I Interventional Open-Label, Non-Randomized Dose-Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-Tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients with Selected Advanced Cancers. Catherine Trial
2024-516660-28-01Locally advanced, recurrent, or metastatic breast, gastric,…
Vall D Hebron Institute Of Oncology
Neoplasms
Spain
17/12/2025
Phase III
An Open-label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of 12-month Treatment with Migalastat in Pediatric Subjects (aged 2 to < 12 years) with Fabry Disease and Amenable GLA Variants
2025-521244-38-00Fabry disease
Amicus Therapeutics Inc.
Nutritional and Metabolic Diseases
Spain, Germany, Belgium
17/12/2025
Phase II
A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2a trial to evaluate the efficacy and safety of BP1.4979 in adult participants with obsessive compulsive disorder
2025-522026-13-00Obsessive compulsive disorder
Bioprojet Pharma
Mental Disorders
Portugal, Spain, Italy, Poland
16/12/2025
Phase III
C3651021: A PHASE 2b/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
2025-522093-36-00Cancer cachexia
Pfizer Inc.
Nutritional and Metabolic Diseases
Slovakia, Italy, Belgium, Germany, Spain, France, Bulgaria, Poland
16/12/2025
Phase I/II
An Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies
2025-522184-15-00Advanced Solid Tumor, Metastatic Solid Tumor
Ipsen Pharma
Neoplasms
Spain, France
16/12/2025
Phase IV
EFFICACY OF FARICIMAB IN PATIENTS WITH SUBRETINAL HYPERREFLECTIVE MATERIAL ASSOCIATED WITH TYPE 2 OR MIXED NEOVASCULAR MEMBRANES ASSESSED BY MULTIMODAL IMAGING
2025-522701-38-00SUBRETINAL HYPERREFLECTIVE MATERIAL
Asociacion Instituto De Investigacion Sanitaria Biobizkaia
Eye Diseases
Spain
15/12/2025
Phase III
FINE-START; A parallel-group, randomized, prospective, interventional, double-blind, multicenter global Phase 3 study to investigate the efficacy and safety of finerenone versus placebo, in participants with chronic kidney disease not using renin-angiotensin-system inhibitors
2025-523075-32-00chronic kidney disease
Universitair Medisch Centrum Groningen
Nutritional and Metabolic Diseases
Spain
15/12/2025
Phase III
A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease
2025-521113-13-00Early Parkinson’s Disease
Biohaven Therapeutics Ltd.
Nervous System Diseases
Germany, France, Italy, Belgium, Czechia, Poland, Austria, Netherlands, Spain, Portugal
15/12/2025
Phase II
A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression “(MAESTRA 1)”
2025-521513-14-00Ovarian Cancer
Incyte Corp.
Neoplasms
Spain, Belgium
12/12/2025
Phase I/II
Phase 1b/2 Trial of OMTX705, an Anti-Fibroblast Activation Protein Antibody-Drug Conjugate, in Combination with Carboplatin, Pemetrexed and Tislelizumab in Patients with Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
2025-521989-95-00Advanced/Metastatic Non-squamous Non-Small Cell Lung Cancer
Oncomatryx Biopharma S.L.
Neoplasms
Spain
12/12/2025
Phase I
A Phase 1b, Prospective, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Tolerability of Multiple Oral Doses of IRL757 in Participants with Parkinson’s Disease and Apathy
2025-523612-37-00Parkinson's Disease and Apathy
Integrative Research Laboratories Sweden AB
Nervous System Diseases
Bulgaria, Poland, Spain, Germany
12/12/2025
Phase I/II
A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0516 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Metastatic Prostate Cancer.
2024-520026-11-00Metastatic Prostate Cancer
AstraZeneca AB
Neoplasms
Italy, Spain, Poland
12/12/2025
Phase III
A Phase 2b/3 Adaptive, Randomized, Active controlled Study Evaluating the Efficacy, Safety, and Tolerability of Povetacicept Versus Calcineurin Inhibitor in the Treatment of Primary Membranous Nephropathy
2025-521661-27-00Primary Membranous Nephropathy
Vertex Pharmaceuticals Inc.
Immune System Diseases
Hungary, Ireland, Czechia, Italy, Spain, Germany, Netherlands
12/12/2025
Phase III
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy With or Without Radiotherapy as Adjuvant Treatment for HER2-Expressing (IHC 3+/2+) Endometrial Cancer (DESTINY-Endometrial02/ GOG-3122/ ENGOT-en30/GINECO)
2024-519444-33-00HER2-expressing endometrial cancer (IHC 3+/2+)
Daiichi Sankyo Inc.
Neoplasms
Germany, Poland, France, Greece, Spain, Portugal, Italy
11/12/2025
Phase II
Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children with Achondroplasia
2024-518072-31-00Achondroplasia
Qed Therapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Norway
10/12/2025
Phase III
Efficacy and Safety of Nipocalimab vs Efgartigimod for Patients with Generalized Myasthenia Gravis in a Randomized, Open-label, Phase 3b, Interventional Trial Including Within Class Switching From Efgartigimod to Nipocalimab
2025-521130-28-00generalized myasthenia gravis
Janssen Cilag International
Immune System Diseases
Austria, Germany, Spain, Italy
10/12/2025
Phase III
A Global, Phase 3, Randomized, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Firmonertinib Compared with Investigator’s Choice of Osimertinib or Afatinib as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic Non-Small-Cell Lung Cancer with Epidermal Growth Factor Receptor P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations (ALPACCA)
2025-522151-26-00Advanced or Metastatic Non-Small-Cell Lung Cancer With Epid…
Arrivent Biopharma Inc.
Neoplasms
Greece, France, Spain, Italy
10/12/2025
Phase III
Comparison of low versus intermediate intravenous dexamethasone doses on rebound pain after ambulatory open foot surgery under popliteal sciatic nerve block: a double-blind clinical trial.
2025-523356-31-01Postoperative pain, Rebound pain after regional anaesthesia
Hospital Universitario Dr Peset Aleixandre
Anesthesia and Analgesia
Spain
10/12/2025
Phase III
AALL2131/EsPhALL2022, An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitor with Blinatumomab in Patients with Newly Diagnosed Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia
2025-520982-39-00Philadelphia Chromosome Positive or ABL-class Philadelphia …
Universita Degli Studi Di Milano Bicocca
Neoplasms
France, Lithuania, Norway, Finland, Spain, Italy, Czechia, Germany, Hungary, Slovakia, Denmark, Austria, Netherlands
09/12/2025
Phase II
A PHASE II TRIAL EVALUATING THE SAFETY AND EFFICACY OF THE COMBINATION OF ZIMBERELIMAB, DOMVANALIMAB, AND SACITUZUMAB GOVITECAN AS FIRST-LINE THERAPY FOR PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER (The ADJUNCT Study)
2025-521489-80-00PD-L1 POSITIVE ADVANCED TRIPLE-NEGATIVE BREAST CANCER
Medica Scientia Innovation Research S.L.
Neoplasms
Spain
09/12/2025
Phase III
CLEOPATTRA: Effects of NNC6019-0001 versus placebo on cardiovascular outcomes in participants with transthyretin amyloid cardiomyopathy (ATTR-CM).
2024-518899-31-00Variant or wild-type transthyretin (TTR) amyloid cardiomyop…
Novo Nordisk A/S
Cardiovascular Diseases
Germany, France, Belgium, Italy, Denmark, Netherlands, Spain, Czechia
09/12/2025
Phase I/II
An Open-label, Multicenter, Phase 1/2a Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of WEF-001 in participants with Advanced KRAS- Mutant Solid Tumours.
2024-518644-21-01Advanced KRAS- Mutant Solid Tumours
Auricula Biosciences Inc.
Neoplasms
Spain
09/12/2025
Phase III
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020
2023-509392-17-00Relapsed Acute Lymphoblastic Leukemia (ALL)
Charite Universitaetsmedizin Berlin KöR
Hemic and Lymphatic Diseases
Netherlands, Czechia, Italy, Spain, Denmark, Austria, Norway, Sweden, Germany, France, Finland, Slovenia
09/12/2025
Phase III
AndroMETa-CRC-064: An Open Label, Randomized, Controlled, Global Phase 3 Study Comparing Telisotuzumab Adizutecan (ABBV-400) Monotherapy to LONSURF (Trifluridine and Tipiracil) plus Bevacizumab in Subjects with Refractory Metastatic Colorectal Cancer Expressing c-Met Protein Level Above a Defined Cutoff
2024-512804-20-00Metastatic Colorectal Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Germany, Poland, France, Italy, Netherlands, Spain
08/12/2025
Phase II
Exploratory Study of Ianalumab in Adults with Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) who Have Previously Benefited from Ianalumab (VAY RE-HIT)
2024-518231-11-00Immune thrombocytopenia (ITP) Warm autoimmune hemolytic an…
Novartis Pharma AG
Hemic and Lymphatic Diseases
Germany, Czechia, Belgium, Spain, Italy, Bulgaria, Romania, France, Hungary
08/12/2025
Phase I
A Study to Evaluate the Pharmacokinetics, Efficacy, Safety and Immunogenicity of Xdivane versus Opdivo® in Patients with Resected Melanoma
2025-522307-14-00Melanoma
Intas Pharmaceuticals Limited
Neoplasms
Spain, Romania
08/12/2025
Phase II
(22419) A randomized, double-blind, placebo-controlled, parallel group Phase 2a study with an extension phase to evaluate the efficacy and safety of BAY 3401016 in participants aged 18 to 45 with Alport syndrome
2024-516471-33-00Chronic kidney disease, Alport Syndrome
Bayer AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Italy, Poland, Czechia, Germany, Portugal, France
05/12/2025
Phase II
A Phase II, Randomized, Open-Label, Parallel Group, Multicenter Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Patients with Multiple Sclerosis
2024-517980-22-00Multiple Sclerosis (MS)
F. Hoffmann-La Roche AG
Immune System Diseases
Poland, Italy, France, Spain, Germany
05/12/2025
Phase IV
Evaluation of the persistency of the preoperative anxiolytic effect of music therapy vs midazolam: electroencephalographic and clinical analysis
2025-522575-29-00Preoperative anxiety
Consorci Mar Parc De Salut De Barcelona
Anesthesia and Analgesia
Spain
05/12/2025
Phase III
(21467) A Phase 3, single-arm, open-label extension study to evaluate the safety of finerenone in addition to standard of care, in pediatric heart failure patients, from birth to 18 years of age, with left ventricular systolic dysfunction (LVSD)
2024-519830-22-00Heart failure due to systemic left ventricular systolic dys…
Bayer AG
Cardiovascular Diseases
Czechia, Germany, Greece, Italy, Finland, Bulgaria, Belgium, Poland, Austria, Portugal, Spain, Hungary, Sweden
05/12/2025
Phase III
(21466) A multicenter, randomized, double-blind, placebo-controlled, Phase 3 study to investigate the efficacy, safety, and PK/ PD of finerenone, in addition to standard-of-care, in pediatric patients, 6 months to < 18 years of age, with heart failure (HF) and left ventricular systolic dysfunction (LVSD)
2024-519829-38-00Heart failure due to systemic left ventricular systolic dys…
Bayer AG
Cardiovascular Diseases
Czechia, Poland, Portugal, Austria, Finland, Greece, Bulgaria, Sweden, Spain, Italy, Belgium, Hungary, Germany
05/12/2025
Phase III
A Phase 3, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled, Multicenter Trial to Confirm the Efficacy and Safety of Glepaglutide 10 mg Twice-Weekly, Followed by a Long-Term, Open-Label Safety Evaluation in Patients with Short Bowel Syndrome–Intestinal Failure (SBS-IF)
2024-512486-14-00Short Bowel Syndrome
Zealand Pharma A/S
Digestive System Diseases
Finland, France, Belgium, Germany, Hungary, Spain, Austria, Netherlands, Italy, Denmark, Czechia, Norway, Poland, Sweden, Estonia
04/12/2025
Phase II
A PHASE 2A, OPEN-LABEL SINGLE ARM MULTICENTER EXPLORATORY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF ORAL DOSES OF ROC-101 IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) AND PULMONARY HYPERTENSION ASSOCIATED WITH INTERSTITIAL LUNG DISEASE (ILD-PH)
2025-522074-37-00Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertensi…
Allrock Bio Inc.
Cardiovascular Diseases
Spain, Italy, Poland, France, Latvia, Germany
04/12/2025
Phase III
A randomized phase III, global, multicentre, open label clinical trial comparing Venetoclax Azacitidine and Quizartinib vs Venetoclax and Azacitidine in newly diagnosed acute myeloid leukemia patient´s ineligible for standard induction chemotherapy.
2025-522979-29-00Acute myeloid leukemia
Fundacion PETHEMA
Neoplasms
Spain, Portugal
04/12/2025
Phase IV
Phase IV, open-label, randomized clinical trial on the effect of intravenous iron on quality of life in elderly patients with Acute Coronary Syndrome.
2025-522421-36-00Acute coronary syndrome
Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVA
Cardiovascular Diseases
Spain
03/12/2025
Phase I
Phase 1 study to investigate the pharmacokinetic profile and safety of 3 testosterone gel formulations in postmenopausal female participants.
2025-522726-12-00No medical conditions.
Chemo Research S.L.
Not possible to specify
Spain
02/12/2025
Phase III
A Randomized, Controlled, Partially Masked, Phase 3b Study to Assess the Injection Burden, Efficacy, Safety, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec (ABBV-RGX-314) in a Real-World Context in Subjects with Neovascular Age-Related Macular Degeneration (nAMD)
2024-512298-28-00Neovascular age-related macular degeneration
AbbVie Deutschland GmbH & Co. KG
Eye Diseases
Czechia, Portugal, Hungary, Spain, Belgium, Italy, Austria, France, Slovakia, Croatia, Germany, Bulgaria, Greece
02/12/2025
Phase I
First-in-Human Study of RO7812653
2025-522101-37-00Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitiv…
F. Hoffmann-La Roche AG
Nervous System Diseases
Sweden, Poland, Spain, Netherlands
02/12/2025
Phase II
C5001004 - A Phase 2, Open-Label Extension Study to Investigate the Safety and Efficacy of PF-07868489 Administered to Adult Participants With Pulmonary Arterial Hypertension
2025-521155-23-00Pulmonary Arterial Hypertension
Pfizer Inc.
Cardiovascular Diseases
Italy, Czechia, Germany, Greece, Spain, Belgium, France
02/12/2025
Phase I/II
A Phase Ib/II, multi-site, open-label, dose finding trial to evaluate the safety, efficacy, and pharmacokinetics of BNT326 in combination with BNT327 in participants with advanced non-small cell lung cancer (NSCLC)
2024-519344-32-00Non-small Cell Lung Cancer
BioNTech SE
Neoplasms
Poland, Germany, Italy, Spain
02/12/2025
Phase III
A phase 3, randomized, double-blind, placebo-controlled, multicenter study with open-label extension to evaluate the efficacy and safety of bimekizumab in study participants with palmoplantar pustulosis
2024-520337-80-00Palmoplantar Pustulosis
UCB Biopharma
Immune System Diseases
Czechia, Denmark, Spain, Poland, Germany, Hungary, Italy, France
02/12/2025
Phase III
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
2025-521382-27-00Moderately to Severely Active Crohn's Disease
Janssen Cilag International
Immune System Diseases
Netherlands, Italy, Portugal, Spain, Czechia, Romania, France, Sweden, Hungary, Belgium, Germany, Greece, Poland
01/12/2025
Phase III
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis
2025-521381-10-00Moderately to Severely Active Ulcerative Colitis
Janssen Cilag International
Digestive System Diseases
Netherlands, Romania, Italy, Spain, Sweden, Czechia, Greece, Hungary, France, Portugal, Belgium, Germany, Poland
01/12/2025
Phase I/II
TulmiSTAR-01: A two-part, Phase I dose escalation and expansion followed by a randomized, open-label multicenter, Phase II study to assess the safety and efficacy of the combination of tulmimetostat (DZR123) and JSB462 (luxdegalutamide) vs standard of care in patients with progressive metastatic castrate resistant prostate cancer
2025-521880-10-00Metastatic castrate resistant prostate cancer (mCRPC)
Novartis Pharma AG
Neoplasms
Italy, Germany, Poland, France, Denmark, Spain
01/12/2025
Phase III
An Open-label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (MK-7962-038)
2025-521970-33-00​​Pulmonary Arterial Hypertension (PAH)
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Czechia, Germany, Sweden, Greece, Croatia, Belgium, Poland, Spain, Portugal, Italy, Denmark, France, Netherlands
01/12/2025
Phase III
A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
2024-520097-36-00Chronic inflammatory demyelinating polyneuropathy (CIDP)
Argenx
Nervous System Diseases
Czechia, Bulgaria, Netherlands, Hungary, Sweden, Slovakia, Slovenia, Greece, Norway, Poland, Italy, Spain, Estonia, Denmark, France, Romania, Portugal, Austria, Germany
01/12/2025
Phase II
A phase 2, multicenter, randomized, placebo-controlled, double-blind study to investigate the safety, pharmacodynamics, and preliminary efficacy of S-606001 as an add-on to enzyme replacement therapy in patients with late-onset Pompe disease.
2025-522146-40-00Late-onset Pompe disease.
Shionogi B.V.
Nutritional and Metabolic Diseases
Belgium, Germany, Denmark, France, Italy, Spain, Netherlands
01/12/2025
Phase II
Evaluation of the safety, tolerability, and effectiveness of CTH120 in adult males with Fragile X syndrome
2025-522972-97-00Fragile X Syndrome
Connecta Therapeutics S.L.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain
01/12/2025
Phase II
A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects with Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants
2024-517393-13-00Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Vertex Pharmaceuticals Inc.
Genetic Phenomena
France, Germany, Italy, Belgium, Spain, Netherlands
28/11/2025
Phase I
A study to find a suitable dose of ASP5834 in adults with solid tumors
2025-522082-29-00Locally advanced (unresectable) or metastatic solid tumor m…
Astellas Pharma Inc.
Neoplasms
Spain, France
28/11/2025
Phase III
A Randomized, Phase 2/3 Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-Paclitaxel and Gemcitabine versus Placebo in Combination With Nab-Paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion
2025-522598-12-00Untreated Metastatic Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Czechia, Austria, Belgium, Ireland, Spain, Germany, Romania, Netherlands, Slovakia, Greece, Poland, Italy, Denmark, France, Sweden
28/11/2025
Phase II
A Phase 2, Multi-Center Study Consisting of a Randomized, Double-Blind, Placebo-Controlled Period, Followed by an Open-Label Extension Period, to Assess the Efficacy, Safety, and Tolerability of Tibulizumab in Adults with Systemic Sclerosis
2024-519335-42-01Systemic Sclerosis
Zura Bio Inc.
Immune System Diseases
Hungary, Romania, Poland, Spain
27/11/2025
Phase II
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2025-520730-28-00Common EGFR-Mutated Locally Advanced or Metastatic Non-Smal…
Janssen Cilag International
Neoplasms
Germany, Spain, Finland, Greece, Portugal, Italy, Belgium, Poland, France
27/11/2025
Phase III
A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 in Combination With Subcutaneous Pembrolizumab and Berahyaluronidase alfa (MK-3475A) Versus MK-3475A in Combination With Pemetrexed/Platinum (Carboplatin or Cisplatin) Chemotherapy as First-line Treatment of Participants With KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC (KANDLELIT-007)
2024-514500-14-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …
Merck Sharp & Dohme LLC
Neoplasms
Germany, Italy, France, Poland, Spain, Hungary, Romania, Greece, Austria, Netherlands, Belgium
27/11/2025
Phase I/II
InsigHHT: A Phase 1/2, Randomized, Double-blind, Placebo-controlled, 2 part Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of Single Dose ALN-6400 in Adult Healthy Volunteers and Multiple Dose ALN 6400 in Adult Patients with Hereditary Hemorrhagic Telangiectasia (HHT)
2025-522510-23-00Hereditary Hemorrhagic Telangiectasia (HHT)
Alnylam Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Spain, Germany
26/11/2025
Phase II
A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
2025-522054-40-00Previously treated advanced melanoma
Iovance Biotherapeutics Inc.
Skin and Connective Tissue Diseases
France, Italy, Germany, Spain
26/11/2025
Phase I
A Phase 1B, Open-Label Study of Mirdametinib in Infants and Toddlers with Neurofibromatosis Type 1 associated Plexiform Neurofibromas
2025-522000-24-00Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofi…
Springworks Therapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Germany
26/11/2025
Phase I/II
A Phase Ib/ II Multicenter, Open-Label, Randomized Study Evaluating the Safety, Pharmacokinetics, and Activity of GDC-4198 Alone and in Combination with Giredestrant in Comparison with Abemaciclib and Giredestrant in Participants with Locally Advanced or Metastatic Estrogen Receptor-Positive, HER2-Negative Breast Cancer who Have Previously Progressed During or After a CDK4/6 Inhibitor
2025-521128-31-00Locally Advanced or Metastatic Estrogen Receptor-Positive, …
Genentech Inc.
Neoplasms
Spain, Italy, France, Germany
26/11/2025
Phase III
Phase 2/3 Adaptive Design, Randomized Double-blind Placebo-controlled Study to Evaluate the Safety and Efficacy of DM199 for the Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
2024-513911-28-00Acute Ischemic Stroke
Diamedica Therapeutics Inc.
Nervous System Diseases
Romania, Hungary, Belgium, Poland, Spain, France
25/11/2025
Phase I
A Phase 1b open label pilot study of CLN-978 for the treatment of moderate to severe systemic lupus erythematosus (SLE)
2024-518780-36-00Systemic Lupus Erythematosus
Cullinan Therapeutics Inc.
Musculoskeletal Diseases
Bulgaria, Romania, France, Germany, Spain, Poland
25/11/2025
Phase III
A multi-center, open-label, drug-drug interaction study to evaluate the effect of pralsetinib (Gavreto) on the pharmacokinetics of CYP3A4, CYP2C8, and CYP2C9 substrates, and hormones estradiol/norethisterone acetate in patients with advanced or metastatic solid tumors.
2025-523158-15-00Patients with advanced or metastatic solid tumors
Rigel Pharmaceuticals Inc.
Neoplasms
Spain
25/11/2025
Phase II
Phase 2 Study to Assess the Efficacy and Safety of SPY002-072 in Adults with Moderately to Severely Active Rheumatologic Disease
2025-521791-63-00Moderately to Severely Active Rheumatologic Disease
Spyre Therapeutics Inc.
Immune System Diseases
Czechia, Poland, Spain, Bulgaria
25/11/2025
Phase III
Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
2024-515023-11-00Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear …
Arcus Biosciences Inc.
Neoplasms
Italy, Spain, Romania, Germany, Netherlands, Poland, France, Czechia, Hungary
24/11/2025
Phase II
A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity
2025-520831-18-00Primary Sjogren’s Disease
Immunovant Sciences GmbH
Immune System Diseases
Germany, Greece, Romania, Spain, Poland, Italy, Hungary
24/11/2025
Phase I/II
A modular Phase I/II, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of AZD4512 monotherapy or in combination with anticancer agent(s) in participants with Acute Lymphoblastic Leukemia
2025-522372-93-00B-cell acute lymphoblastic leukemia (B-ALL)
AstraZeneca AB
Hemic and Lymphatic Diseases
Spain
24/11/2025
Phase I
Study of Q702 in Subjects with Relapsed or Refractory Chronic Graft-versus-Host Disease (cGVHD)
2025-522680-14-00Chronic Graft-versus-Host Disease
Qurient Co. Ltd.
Immune System Diseases
Spain
24/11/2025
Phase I
Study of GS-5319 in Adults With Solid Tumors
2025-522397-36-00Advanced solid tumors
Gilead Sciences Inc.
Neoplasms
Spain
24/11/2025
Phase III
A randomized, double-blind, placebo-controlled, parallel-group, multicenter study of the efficacy and safety of depemokimab in adult participants with COPD with Type 2 inflammation.
2024-520418-22-00Chronic Obstructive Pulmonary Disease
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Slovakia, Denmark, France, Sweden, Ireland, Belgium, Netherlands, Spain, Croatia, Germany, Poland, Hungary, Norway, Portugal
24/11/2025
Phase I
A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment
2024-517923-38-00Newly diagnosed and/or previously treated IDH1-mutated mali…
Institut De Recherches Internationales Servier IRIS
Neoplasms
Czechia, Spain
24/11/2025
Phase II
A Phase II, Multicenter, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of RO7790121 in Patients with Moderate to Severe Rheumatoid Arthritis who have an Inadequate Response or Intolerance to TNF and/or JAK Inhibitors
2025-521034-28-00Moderate to Severe Rheumatoid Arthritis (RA)
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy, Denmark, France, Poland, Germany, Spain, Belgium
23/11/2025
Phase I/II
A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants with Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors
2025-521672-60-00Metastatic or locally advanced SST2-positive neuroendocrine…
Crinetics Pharmaceuticals Inc.
Neoplasms
Spain, France, Germany, Italy
21/11/2025
Phase I/II
A Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5764227 in combination with Standard of Care (SoC) or other agents in Participants with Advanced Solid Tumors
2025-522274-37-00Neoplasms
Glaxosmithkline Research & Development Limited
Neoplasms
Spain
21/11/2025
Phase III
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration (4FRONT-2)
2025-521349-25-00Macular neovascularization secondary to age-related macular…
4d Molecular Therapeutics Inc.
Eye Diseases
Germany, Italy, Hungary, Bulgaria, Lithuania, France, Spain, Latvia, Portugal
21/11/2025
Phase II
A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of ALXN1920 in Adult Participants with PMN (Primary Membranous Nephropathy) who are at a High Risk for Disease Progression (AUTUMN)
2025-520780-40-00Primary Mebranous Nephropathy (PMN)
Alexion Pharmaceuticals Inc.
Immune System Diseases
Spain, France, Italy
20/11/2025
Phase II
A Global Phase 2b, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients with Symptomatic Non Obstructive Hypertrophic Cardiomyopathy – FORTITUDE-HCM
2024-515125-28-00Non-obstructive hypertrophic cardiomyopathy
Imbria Pharmaceuticals Inc.
Cardiovascular Diseases
Austria, Germany, Belgium, France, Portugal, Spain, Netherlands, Italy, Poland
20/11/2025
Phase III
A Double-blind, Randomized, Psychoactive Placebo-controlled Study to Evaluate the Efficacy and Safety of Intranasal Esketamine 84 mg in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder in Adolescent Participants with Acute Suicidal Ideation or Behavior
2024-518615-19-00Major Depressive Disorder
Janssen Cilag International
Mental Disorders
Italy, Hungary, Spain, Romania
19/11/2025
Phase I/II
A multi-center, open-label Phase 1/2 study to evaluate the safety, efficacy, PK and PD of ONA-255 in study participants with advanced cancer
2025-522233-62-00Advanced cancer; breast cancer; metastatic gastric / gastro…
Ona Therapeutics S.L.
Neoplasms
Spain
19/11/2025
Phase III
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate Coadministered With Rosuvastatin in Adults With Hyperlipidemia
2025-521495-54-00Hyperlipidemia
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Spain, Hungary
19/11/2025
Phase I
A Study to Learn About the Study Medicine Called PF-07258669 in Older Adults Including Those at Risk of Malnutrition
2025-520763-41-00Older adults at risk of malnutrition
Pfizer Inc.
Not possible to specify
Spain
19/11/2025
Phase II
Evaluation of the effect of intravenous lidocaine on the systemic inflammatory response associated with cardiopulmonary bypass in patients undergoing elective valvular and coronary cardiac surgery: A randomized double-blind clinical trial.
2025-523534-11-00Patients undergoing elective cardiac valve surgery and/or c…
Hospital San Pedro
Anesthesia and Analgesia
Spain
19/11/2025
Phase I/II
Phase 1/2 Study of PYX-201 in Combination with Pembrolizumab in Advanced Solid Tumors
2025-521828-30-00Advanced Solid Tumors
Pyxis Oncology Inc.
Neoplasms
France, Spain, Poland
19/11/2025
Phase III
A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
2025-522860-34-00Small lymphocytic lymphoma (SLL), Chronic lymphocytic leuke…
BeOne Medicines AG
Neoplasms
Sweden, Belgium, Spain, Germany, Austria, Netherlands, Italy, Romania, Poland, France
18/11/2025
Phase III
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of JNJ-78278343, a T-cell-redirecting Agent Targeting Human Kallikrein 2 Versus Placebo for Metastatic Castration-resistant Prostate Cancer
2025-520927-26-00Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Cilag International
Neoplasms
France, Belgium, Spain, Poland, Italy, Netherlands, Germany
18/11/2025
Phase I/II
C5731006 - A PHASE 1B/2, OPEN-LABEL, MULTICOHORT STUDY OF DISITAMAB VEDOTIN IN ADULTS WITH HER2 EXPRESSING ADVANCED BREAST CANCER
2025-521003-52-00HER2 Expressing Advanced Breast Cancer
Pfizer Inc.
Neoplasms
Germany, Spain, Italy
18/11/2025
Phase III
C1091009 - A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY PREGNANT WOMEN AND THEIR INFANTS
2022-503070-36-00Group B streptococcus (GBS) disease
Pfizer Inc.
Bacterial Infections and Mycoses
Finland, Netherlands, Spain
18/11/2025
Phase III
Randomised, Multicentre, Multinational, Double-Blind Integrated Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 (Proposed Nivolumab Biosimilar) Versus EU-/US-Opdivo in Subjects With Previously Untreated Advanced (Unresectable or Metastatic) Melanoma (LEON Study)
2025-521562-95-00Previously Untreated Advanced (Unresectable or Metastatic) …
Mabxience Research S.L.
Musculoskeletal Diseases
Italy, Spain, Slovakia, Romania, Portugal, Greece, Poland
18/11/2025
Rows per page Showing 701–800 of 1016
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-europe/country/spain?page=8

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,490 trial records at the last sync on 25 Sep 2026, 03:16 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 1,016 of those trials with a site in Spain.

How many recently authorised EU trials have a site in Spain?

1,016 of the 2,500 most recently authorised trials in this register list a site in Spain; 422 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.